Cushing’s Disease in Dogs Part 3: Current & Investigative Options for Therapy
Commonly used treatments in the management of Cushing's disease in dogs, or PHD, are mitotane and trilostane.
Canine pituitary dependent hyperadrenocorticism (PDH), also known as Cushing’s disease, is a common endocrine disorder in older dogs. This disorder is caused by a pituitary adenoma (PA) that secretes inappropriate amounts of adrenocorticotropic hormone (ACTH), which results in bilateral adrenal hyperplasia and disorderly and excessive production of cortisol by the adrenal gland.
Read the first 2 articles of this series:
- Part 1: Comparative Epidemiology & Etiology in Dogs & Humans (November/December 2015)
- Part 2: Diagnostic Approach (January/February 2016)
THERAPEUTIC APPROACHES TO CUSHING’S DISEASE
In humans, while pituitary surgery is considered first-line treatment for patients with Cushing’s disease,1 medical therapy now plays a more important role in the armamentarium available to patients if surgery is not successful.2,3 Repeat surgery, bilateral adrenalectomy, and pituitary radiation are also frequently employed.1
In dogs, medical management is far more common than surgical approaches and generally involves the use of medications directed toward reducing adrenal glucocorticoid production.4,5 However, recent work on newer medical and surgical therapies and emerging treatments provides the clinician with multiple therapeutic options.
Medical treatments can be classified based on their mechanism of action and categorized as (Table 1):
- Adrenal-directed steroidogenesis inhibitors or adrenolytics
- Centrally acting agents
- Glucocorticoid receptor blockers.
In dogs, o,p’-DDD, also known as mitotane (Lysodren, bms.com), trilostane (Vetoryl, dechra .com), and ketoconazole (in many countries outside of the U.S.), are the most commonly used agents for canine Cushing’s disease, although several other agents have been used or are under investigation (Table 2).
Mitotane is a potent adrenocorticolytic agent derived from the insecticide dichlorodiphenyltrichloroethane (DDT). The goal of mitotane therapy is to achieve both pre- and post-cortisol measurements in the normal resting range (2–6 mcg/dL).
Pharmacodynamics. The drug causes progressive necrosis of the zona fasciculata and zona reticularis of the adrenal gland and, at higher doses, may also cause necrosis of the zona glomerulosa. Other effects of mitotane include fatty degeneration, centrilobular atrophy, and congestion of the liver.
Healthy dogs with and without hyperadrenocorticism (HAC) are usually quite resistant to the effects of the drug, but some may show adverse effects, such as gastric irritation, hypoadrenocorticism, and, very occasionally, neurologic signs.
Initial Therapy. Mitotane therapy is begun at a dose of 50 mg/kg, divided, Q 12 H.6,7 In dogs with significant nonadrenal illness, the dose of mitotane may be reduced by 50% and adjusted upward based on clinical and hormonal response. Administering the drug with food improves its gastrointestinal absorption. At induction doses, mitotane is typically administered for 5 to 10 days, until water consumption decreases to less than 100 mL/kg/day. At this point, the dog should be reevaluated and an ACTH stimulation test performed.
In patients that are not demonstrating polydipsia, or those in which water consumption cannot be monitored or polydipsia is due to another underlying disease (eg, diabetes mellitus), mitotane should be administered for a maximum of 5 to 7 days prior to ACTH stimulation testing.
Mitotane should be discontinued immediately if decreased appetite, depression, diarrhea, or vomiting is observed.
Maintenance Therapy. Maintenance therapy (50 mg/kg Q 7–10 days or 25 mg/kg Q 3 days) is started once the ACTH stimulation test demonstrates adequate suppression (pre- and post-cortisol measurements of ≥ 3 and ≤ 5 mcg/dL, respectively) and prednisone therapy (if necessary) has been discontinued (see Role of Prednisone). Failure to use maintenance therapy results in regrowth of the adrenal cortex and recurrence of clinical signs.
Efficacy of maintenance therapy is monitored by ACTH stimulation tests 1 month after initiation of maintenance therapy and every 3 to 4 months thereafter. The total weekly dose of mitotane required for long-term maintenance is quite variable (26–330 mg/kg/week), but therapy should always begin with the recommended initial dosage; then titrated to effect based on subsequent ACTH stimulation test results. If clinical signs return in conjunction with elevated cortisol concentrations post ACTH stimulation, the patient can be managed with higher, or more frequent, maintenance doses or a return to the induction protocol outlined in Initial Therapy.
Role of Prednisone. Glucocorticoids were typically administered in combination with mitotane therapy for many years, but it is no longer common to administer these drugs concurrently. However, prednisone therapy (0.2–0.5 mg/kg/day) should be initiated in patients with clinical signs of hypocortisolemia until results of the ACTH stimulation test are known.
A small supply of prednisone should be made available to the owner in the event of overdose of mitotane. However, dexamethasone can be used preferentially for emergency situations because it does not interfere with measurement of serum cortisol concentrations.
Treatment Considerations. Reasons for mitotane treatment failure include:
- Incorrect diagnosis
- Presence of an adrenal tumor (although some adrenal tumors do respond well)
- Loss of drug potency due to poor storage or compounding of mitotane
- Need for a higher dose or duration of treatment in some dogs.
Note that phenobarbital enhances the metabolism of mitotane, leaving it ineffective. Therefore, patients with Cushing’s disease and idiopathic epilepsy should be treated with other anticonvulsant drugs (eg, potassium bromide, levetiracetam).
Median survival time of 200 dogs treated with mitotane was 2.2 years (range, 10 days–8.2 years).6
Trilostane is a synthetic, hormonally inactive steroid analogue, which is a competitive inhibitor of the 3-beta-hydroxysteroid dehydrogenase system.
Pharmacodynamics. Trilostane blocks synthesis of adrenal steroids, including cortisol and aldosterone.8-14 It is rapidly absorbed orally (peak concentrations within 1.5 H), although suppression of plasma cortisol concentrations is short lived (< 20 H).
Trilostane is well tolerated in most dogs. Adverse effects are usually mild and self-limiting, and include diarrhea, vomiting, and lethargy in up to 63% of treated dogs.8,9 However, the percentage of dogs that develop adverse events is much lower when they are treated with current recommended (lower) starting doses. There have been anecdotal reports of acute death shortly after initiating trilostane treatment.
Initial Therapy. Current recommendations for trilostane use specify administration of an initial dose of 1 to 2 mg/kg Q 12 to 24 H. This dose is then increased or decreased based on evaluation of ACTH stimulation test results.15-17 Trilostane should be administered with food, including the days that ACTH stimulation tests are performed, to aid in absorption. Whenever possible the brand name preparation (Vetoryl, dechra.com) should be used to avoid inconsistencies in dose seen when using compounded medications.
ACTH stimulation testing should be performed 10, 30, and 90 days after initiation of treatment; then 30 days after each dose adjustment.18-21 While samples for testing can be collected either 4 or 6 H after drug administration, it is important that the same sampling time—4 or 6 H—always be maintained for a specific patient.
Maintenance Therapy. Hormonal end points are post cortisol concentrations less than 6 to 9 mcg/dL, in conjunction with remission of clinical signs. In patients that fail to reach clinical remission with continued elevations in post ACTH cortisol concentrations, the dose of trilostane should be increased by 25% and the pet retested in 7 to 10 days. If post ACTH cortisol concentrations demonstrate adequate hormonal control but clinical signs persist, twice daily dosing may be indicated. If you are switching from once daily to twice daily dosing, the once daily dose should be split in half and administered Q 12 H. For example, if the patient was initially on 60 mg Q 24 H, the dose would be changed to 30 mg Q 12 H.
Compared with higher doses administered Q 24 H, twice daily therapy, at a starting dose of 1 to 3 mg/kg, may:
- Result in good control of clinical signs, with less risk of adverse effects
- Be more effective at consistently controlling hypercortisolemia throughout the day
- Be appropriate as a starting dose in dogs with diabetes and other related complications of Cushing’s disease.22-26
Treatment Considerations. Occasionally, dogs receiving trilostane have developed hypoadrenocorticism, which is generally glucocorticoid deficient only, although dogs with evidence of mineralocorticoid deficiency have been reported. Trilostane-induced hypoadrenocorticism is generally reversible but, in rare cases, this may take several months, most likely due to adrenocortical necrosis. See Consider This Case, for a case example of trilostane therapy in a dog with PDH.
Mitotane Versus Trilostane for Canine Cushing’s Disease
Studies have compared trilostane and mitotane therapy in dogs with PDH or adrenal tumors.27-31 In a retrospective study of dogs treated with either mitotane (n = 25) or trilostane (n = 123), long-term survival was not statistically different between the groups. Median survival in the mitotane group was 708 days (range, 33–1399) and, in the trilostane group, 662 days (range, 8–1971). Of the dogs that died in this study, 11% died due to causes attributed to the underlying PDH, and a further 17% died of causes that may have been related to underlying PDH. In 38% of cases, cause of death could not be directly attributed to PDH and, in 34%, the cause of death was unknown.31
While ketoconazole was used more frequently in the past,32,33 its use now is generally in countries where mitotane and trilostane are not available, or when these agents have failed to correct hypercortisolism or resulted in adverse reactions. Its systemic use has recently been restricted or banned in several countries due to potential of significant hepatotoxicity in humans.
Pharmacodynamics. Specifically, ketoconazole has been shown to inhibit cholesterol side-chain cleavage enzyme, which converts cholesterol to pregnenolone, 17-alpha-hydroxylase, and 17,20-lyase—which convert pregnenolone into androgens—and 11-beta-hydoxylase, which converts 11-deoxycortisol to cortisol.
Efficacy. One study examined the safety and efficacy of ketoconazole in 48 dogs with PDH.34 Data collected from each record included signalment, clinical signs, results of ACTH stimulation tests before and after treatment with ketoconazole (10 mg/kg PO Q 12 H), serum alkaline phosphatase (ALP) and alanine aminotransferase (ALT) activities, dosage of ketoconazole, clinical response, and survival time.
Forty-three of 48 dogs (90%) had evidence of clinical improvement during the treatment period. In all dogs, treatment with ketoconazole resulted in significantly lower serum cortisol concentrations before and after ACTH stimulation testing; 69% (33/48) of serum cortisol concentrations measured after ACTH stimulation were within the basal resting range. Serum ALP and ALT activities significantly decreased after treatment with ketoconazole.
Prognosis. Survival time after diagnosis of PDH ranged from 2 to 61 months (mean, 26.9 months; median, 25 months).34 Another study evaluating ketoconazole found that after diagnosis, 50% of the dogs died approximately 1.8 to 2 years (range, 0.6–3) after starting therapy.35
Additional Therapeutic Options
Several other adrenal steroidogenesis inhibitors have been used in humans and, at times, in dogs (Table 2).36,37
Consider This Case
A 10-year-old castrated male cocker spaniel was referred for evaluation of severe polyuria and polydipsia (PU/PD) of 3 months duration.
On physical examination no significant abnormalities were detected, with the exception of mild hepatomegaly. The skin and hair coat appeared to be normal.
Previous laboratory analysis, including a complete blood count and serum biochemical profile, was unremarkable, with the exception of a urine specific gravity (USG) of 1.010 and positive urine culture for Escherichia coli. The pet was treated with enrofloxacin (5 mg/kg Q 24 H) for 10 days; however, no change in the PU/PD was observed.
An ACTH stimulation test was performed, with a resting cortisol and 1-hour post cortisol results of 2.7 and 14.8 mcg/dL, respectively. These results were considered normal for the laboratory.
HAC was still considered to be the most likely differential cause for the PU/PD, despite the previously normal ACTH stimulation test, given the signalment, history, and clinical signs.
A low-dose dexamethasone suppression test (LDDS) was performed following IV administration of 0.01 mg/kg of dexamethasone. The resting cortisol, 4-hour post LDDS, and 8-hour post LDDS results were 5.1 (reference range, 1.4–5 mcg/dL), 1.2, and 4.6 mcg/dL, respectively.
The elevated 8-hour cortisol (reference range, < 1.4 mcg/dL), in combination with greater than 50% suppression in cortisol concentrations seen at 4 hours, was diagnostic of PDH.
Treatment options were discussed with the referring veterinarian and treatment with trilostane (Vetoryl) was recommended, starting with 2 mg/kg PO Q 24 H in the morning.
The owner was instructed to:
- Administer the medication with food to enhance gastrointestinal absorption
- Monitor the animal’s water consumption, urination, appetite, and activity level
- Observe for any adverse reactions, such as vomiting and diarrhea.
A recheck examination consisting of a physical examination and ACTH stimulation test with monitoring of electrolytes was scheduled 10 days following the start of medication.
At the time of the recheck examination, the owners reported a marked reduction in the PU/PD. An ACTH stimulation test was performed 4 hours post administration of trilostane, with pre and post ACTH cortisol concentrations 2.2 and 5.4 mcg/dL, respectively, indicating adequate adrenal suppression. Determination of electrolytes with an in-house chemistry analyzer was performed and sodium and potassium concentrations were within normal limits.
Due to the laboratory results, along with the observed improvement in clinical signs, the current dose of trilostane was continued and the pet scheduled for a recheck examination in 4 weeks.
During the subsequent recheck examination, the owners reported that the pet was more active, with normal water consumption and urination. A morning urine sample collected by the owner demonstrated a USG of 1.028. Electrolytes were within normal limits. The pre and post cortisol concentrations were 1.4 and 4.8 mcg/dL, respectively, indicating continued adequate adrenal suppression. The dose of trilostane was maintained and the pet scheduled for a recheck examination in 3 months.
Three- and 6-Month Rechecks
Three and 6 months later the pet was clinically normal. One episode of vomiting and diarrhea had occurred at 4.5 months, but the patient responded to the use of a bland diet, and clinical signs resolved in 24 hours, with no adjustments made to the treatment protocol. At the 3- and 6-month recheck examinations, electrolyte concentrations were within normal limits and post ACTH cortisol concentrations were less than 4.2 and 5 mcg/dL, respectively. The dose of trilostane was maintained and the pet scheduled for a recheck examination in 3 to 4 months.
This case illustrates several important points regarding Cushing’s disease and its treatment with trilostane. The referring veterinarian had 3 questions regarding this patient’s presentation and diagnostic results:
- The lack of clinical signs of Cushing’s disease other than PU/PD
- The normal initial ACTH stimulation test
- The finding of normal serum ALP on the initial laboratory evaluation.
PU/PD may be the only clinical sign of HAC. Dermatologic abnormalities, such as bilateral symmetric endocrine alopecia and pyoderma, need not be present.
ACTH Stimulation Test
Up to 15% to 20% of dogs with HAC have a normal ACTH stimulation test upon initial evaluation of the pituitary–adrenal axis. When faced with a patient that has clinical signs indicative of HAC but a normal ACTH stimulation test, consider LDDS to establish a diagnosis or rule out HAC. Conversely, up to 10% of dogs have an initially normal LDDS; therefore, if LDDS is used as the initial screening test and a normal test result is obtained, consider an ACTH stimulation test.
Serum ALP Results
Up to 20% of dogs do not have an elevated ALP in response to either exogenous or endogenous steroid excess, likely due to lack of the gene encoding for the steroid inducible isoenzyme.
The target hormonal goal for the ACTH stimulation test is considered a post ACTH cortisol of less than 9.1 mcg/dL. Together with improvement in clinical signs, this level of adrenal suppression indicates appropriate dosing with trilostane. In our hands, up to 80% of patients obtain clinical and hormonal improvement with once daily dosing.
Recent work on somatostatin and dopaminergic receptor changes in humans and dogs with Cushing’s disease has opened the door to targeted therapy of pituitary tumors. Such therapies not only result in decreased ACTH production but a reduction in tumor size. Several agents have been studied or are in clinical trials (Table 3).
The monoamine oxidase B inhibitor selegiline (L-deprenyl), which raises concentrations of dopamine in the brain, has been used to treat hyperadrenocorticism in dogs.43 The medication appears effective in 20% to 30% of patients with pars intermedia disease, with few side effects.44 Currently, it is used in PDH patients in which the cost of monitoring ACTH stimulation tests and electrolytes prohibits treatment with adrenal enzyme blockers or adrenolytics.
Several groups have described the successful use and complications associated with administration of transsphenoidal hypophysectomy (TSH) in dogs with PDH.45-47
Recently, Mamelak and colleagues described a technique for transsphenoidal removal of pituitary adenomas in 26 dogs with PDH using a high definition video telescope.47 Pituitary tumors were removed using a modified transoral transsphenoidal approach, and localization of the sella was performed by drilling pilot holes in the basisphenoid bone, followed by computed tomography. Sustained tumor control and hormonal remission based on normalized ACTH and urine cortisol creatinine ratio (UCCR) measurements were observed in 20/21 (95%) of dogs one year post surgery.
Tumor Size. In the study by Mamelak and colleagues,47 all dogs had tumors with pituitary height/brain area (P/B) ratios greater than 0.32 and a median P/B ratio of 0.73. Median tumor volume was 820 mm3, which is 9 times larger than the median volume of 89 mm3 reported by Hanson and colleagues, whose study reported mean tumor height of 6 mm, mean width of 6.2 mm, and mean height of 5.4 mm, with a median P/B ratio of 0.3. Forty-three percent of the dogs had a normal P/B ratio.45
Interestingly, Hanson and colleagues concluded that pituitary size (height) was the most significant predictor of postoperative survival and mortality.45 In those studies, initial remission of PDH occurred in 85% of dogs, with relapse in 28% by 3 years. Similarly, Hara and colleagues evaluated outcomes in 25 dogs that underwent TSH using the protocol of Meij and colleagues.46 Median P/B ratio was 0.38 (range, 0.24–0.71), and 24% of dogs had a normal P/B ratio.
Survival. Surgical experience is likely an important variable in dogs undergoing TSH. In the study by Hanson and colleagues, survival at 1, 2, 3, and 4 years were 86%, 83%, 80%, and 79% in 181 patients, respectively.45 Disease free intervals (DFIs) were 90%, 77%, 72%, and 68%, respectively.
In the study by Hara and colleagues, initial remission was attained in 84% of dogs, with 12% relapsing within 4 years. Survival rates at 1, 2, 3, and 4 years was 92%, 81%, 81%, and 81%, respectively.46 No data on DFIs were reported.
In the study by Mamelak and colleagues, 1-year survival was 81%, with all 5 deaths occurring within the first 5 days, with 100% of the surviving dogs in remission at 3 months and 95% in remission at 1 year. To date, 7 dogs have survived greater than 2 years and 1 dog greater than 3 years.47
Further Investigation. Continued experience with surgery to remove pituitary tumors in both dogs and cats is important to not only improve survival and DFIs but also facilitate continued collection of tumor tissue, allowing for additional studies on pathogenesis of this disease and novel therapies for both humans and pets.
The most commonly used treatments in the management of PDH are mitotane and trilostane. Most clinicians prefer the use of trilostane, given similar efficacy and fewer side effects when compared with mitotane, especially at the lower dosages currently being recommended. In the future, expanded use of TSH and medications that are pituitary—rather than adrenal—directed should help increase survival and improve the quality of life of patients diagnosed with PDH.
ACTH = adrenocorticotropic hormone; ALP = alkaline phosphatase; ALT = alanine aminotransferase; a-MSH = alpha-melanocyte stimulating hormone; DDT = dichlorodiphenyltrichloroethane; DFI = disease free interval; EGFR = epidermal growth factor receptor; HAC = hyperadrenocorticism; LDDS = low-dose dexamethasone suppression; PA = pituitary adenoma; P/B = pituitary height/brain area; PDH = pituitary dependent hyperadrenocorticism; POMC = proopiomelanocortin; PU/PD = polyuria/polydipsia; SSR = somatostatin receptor; TSH = transsphenoidal hypophysectomy; UCCR = urine cortisol creatinine ratio; USG = urine specific gravity
Read More on Cushing’s Disease in Dogs
- Nieman L, Biller B, Findling J, et al. Treatment of Cushing’s syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015; 100(8):2807–2831.
- Cuevas-Ramos D, Fleseriu M. Treatment of Cushing’s disease: A mechanistic update. J Endocrinol 2014: 223:R19-R39.
- Lau D, Rutledge C, Aghi M. Cushing’s disease: Current medical therapies and molecular insights guiding future therapies. Neurosurg Focus 2015; 38(2):1-10.
- de Bruin C, Meij BP, Kooistra HS, et al. Cushing’s disease in dogs and humans. Horm Res 2009; 71:140-143.
- Braddock JA. Medical treatment of hyperadrenocorticism in the dog. Aust Vet J 2003; 81(1-2):31-33.
- Kintzer P, Peterson M. Mitotane (o,p’-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1999; 5:182-190.
- den Hertog E, Braakman J, Teske E, et al. Results of non-selective adrenocorticolysis by o, p’-DDD in 129 dogs with pituitary dependent hyperadrenocorticism. Vet Rec 1999; 144:12-17.
- Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002; 63(4):506-512.
- Neiger R, Ramsey I, O’Connor J, et al. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002; 150(26):799-804.
- Braddock JA, Church DB, Robertson I, et al. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 2003; 81(10):600-607.
- Wenger M, Sieber-Ruckstuhl NS, Müller C, et al. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 2004; 65(9):1245-1250.
- Sieber-Ruckstuhl N, Boretti F, Wenger M, et al. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Dom Anim Endocrinol 2006; 31:63-75.
- Bell R, Neiger R, McGrotty Y, Ramsey IK. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Vet Rec 2006; 159(9):277-281.
- Sieber-Ruckstuhl NS, Boretti FS, Wenger M, et al. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Vet Rec 2008; 163(16):477-481.
- Feldman EC, Kass PH. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med 2012; 26(4):1078-1080.
- Cho KD, Kang JH, Chang D, et al. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2013; 27(1):91-98.
- Fracassi F, Corradini S, Floriano D, et al. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane. Vet Rec 2015; 176(2):49-54.
- Reid LE, Behrend EN, Martin LG, et al. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2014; 28(2):443-450.
- Griebsch C, Lehnert C, Williams GJ, et al. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2014; 28(1):160-165.
- Burkhardt WA, Boretti FS, Reusch CE, et al. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism. J Vet Intern Med 2013; 27(4):919-923.
- Cook AK, Bond KG. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism. JAVMA 2010; 237(7):801-805.
- Alenza DP, Arenas C, Lopez ML, Melian C. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. JAAHA 2006; 42(4):269-276.
- Feldman EC. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. JAVMA 2011; 238(11):1441-1351.
- Augusto M, Burden A, Neiger R, Ramsey I. A comparison of once and twice daily administration of trilostane to dogs with hyperadrenocorticism. Tierarztl Prax Ausg K Kleintiere Heimtiere 2012; 40(6):415-424.
- Arenas C, Melián C, Pérez-Alenza MD. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: A comparison between mitotane and twice daily trilostane treatment. J Vet Intern Med 2014; 28(2):473-480.
- Braun C, Boretti FS, Reusch CE, et al. Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism. Schweiz Arch Tierheilkd 2013; 155(10):551-558.
- Arenas C, Melián C, Pérez-Alenza MD. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: Twice daily versus once daily. J Vet Intern Med 2013; 27(6):1478-1485.
- Reine NJ. Medical management of pituitary-dependent hyperadrenocorticism: Mitotane versus trilostane. Top Companion Anim Med 2012; 27(1):25-30.
- Helm JR, McLauchlan G, Boden LA, et al. A comparison of factors that influence survival in dogs with adrenal dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med 2011; 25(2):251-260.
- Clemente M, De Andrés PJ, Arenas C, et al. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2007; 161(24):805-809.
- Barker EN, Campbell S, Tebb AJ, et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19(6):810-815.
- Peterson ME. Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing’s disease). Vet Clin North Am Small Anim Pract 2001; 31(5):1005-1014.
- Feldman E, Bruyette D, Nelson R. Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism. JAVMA 1990; 197:71-78.
- Lien YH, Huang HP. Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994-2007). JAVMA 2008; 233(12):1896-1901.
- Castillo V, Gomez N, Lalia J, et al. Cushing’s disease in dogs: Cabergoline treatment. Res Vet Sci 2008; 85(1):26-34.
- Daniel E, Newell-Price J. Steroidogenesis enzyme inhibitors in Cushing’s syndrome. Eur J Endocrinol 2015; 17:263-280.
- Fleseriu M, Petersenn S. Medical therapy for Cushing’s disease: Adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers. Pituitary 2015; 18:245-252.
- Pérez AM, Guerrero B, Melián C, et al. Use of aminoglutethimide in the treatment of pituitary-dependent hyperadrenocorticism in the dog. J Small Anim Pract 2002; 43(3):104-108.
- Orth DN, Peterson ME, Drucker WD. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Cushing’s syndrome: Diurnal rhythm and responses to various stimuli. Endocrinol 1988; 122(4):1250-1262.
- Dodam JR, Kruse-Elliott KT, Aucoin DP, Swanson CR. Duration of etomidate-induced adrenocortical suppression during surgery in dogs. Am J Vet Res 1990; 51(5):786-788.
- Kruse-Elliott KT, Swanson CR, Aucoin DP. Effects of etomidate on adrenocortical function in canine surgical patients. Am J Vet Res 1987; 48(7):1098-1100.
- Bertagna X, Pivonello R, Fleseriu M. LCI699, a potent 11 beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: Results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 2014; 99(4):1375-1383.
- Bruyette D. Canine pituitary-dependent hyperadrenocorticism: A spontaneous animal model for neurodegenerative disorders and their treatment with L-deprenyl. In Yu P, Tipton K, Boulton A (eds): Current Neurochemical and Pharmacological Aspects of Biogenicamines. Prog Brain Res 1995; 106:207-215.
- Peterson ME. Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing’s disease). Vet Clin North Am Small Anim Pract 2001; 31(5):1005-1014, viii.
- Hanson JM, Teske E, Voorhout G, et al. Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg 2007; 107(4):830-840.
- Hara Y, Teshima T, Taoda T, et al. Efficacy of transsphenoidal surgery on endocrinological status and serum chemistry parameters in dogs with Cushing’s disease. J Vet Med Sci 2010; 72(4):397-404.
- Mamelak AN, Owen TJ, Bruyette D. Transsphenoidal surgery using a high definition video telescope for pituitary adenomas in dogs with pituitary dependent hypercortisolism: Methods and results. Vet Surg 2014; 43(4):369-379.
- Castillo V, Theodoropoulou M, Stalla J, et al. Effect of SOM230 (pasireotide) on corticotropic cells: Action in dogs with Cushing’s disease. Neuroendocrinol 2011; 94:124-136.
- Robben JH, van den Brom WE, Mol JA. Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. Res Vet Sci 2006; 1:25-32.
- Pivonello R, Ferone D, De Herder W, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89:2452-2462.
- Petrossians P, Thonnard A, Beckers A. Medical treatment in Cushing’s syndrome: Dopamine agonists and cabergoline. Neuroendocrinol 2010; 92:116-119.
- Bondioni S, Angioni A, Corbetta S. Effect of 9-cis retinoic acid on dopamine d2 receptor expression in pituitary adenoma cells. Exp Biol Med 2008; 233(4):439-446.
- Giraldi F, Ambrogio A, Andrioli M. Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 2012; 97(10):3577-3583.
- Castillo V, Giacomini D, Páez-Pereda M. Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinol 2006; 147(9):4438-4444.
- Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 2011; 121:4712-4721.